Lenalidomide (Revlimid®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis

Experimental Neurology

Volumn 220, Issue 1, 2009, Pages 191-197

  Neymotin, Arie ^a   Petri, Susanne ^c   Calingasan, Noel Y ^a   Wille, Elizabeth ^a   Schafer, Peter ^b   Stewart, Charles ^d   Hensley, Kenneth ^d   Beal, M Flint ^a   Kiaei, Mahmoud ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CELGENE CORPORATION   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

FasL; G93A; Inflammation; Lenalidomide; SOD1; TNF

Indexed keywords

CD40 LIGAND; CYTOKINE; FAS LIGAND; INTERLEUKIN 1BETA; LENALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; THALIDOMIDE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LUMBAR SPINAL CORD; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NISSL STAINING; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; SURVIVAL; SYMPTOM; UPREGULATION; WEIGHT REDUCTION; ANIMAL; ANIMAL LAMENESS; BODY WEIGHT; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; MOTONEURON; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; SURVIVAL RATE; TRANSGENIC MOUSE; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; LAMENESS, ANIMAL; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NERVE DEGENERATION; SPINAL CORD; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 70349751944     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.08.028     Document Type: Article

References (21)

1. Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A.P., Chen C., and Przedborski S. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 49 (2001) 176-185
2. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4 (2004) 314-322
3. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., and Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312 (2006) 1389-1392
4. Bruijn L.I., Miller T.M., and Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27 (2004) 723-749
5. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., Patterson R.T., Stirling D.I., and Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 163 (1999) 380-386
6. Gowing G., Dequen F., Soucy G., and Julien J.P. Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J. Neurosci. 26 (2006) 11397-11402
7. Gowing G., Philips T., Van Wijmeersch B., Audet J.N., Dewil M., Van Den Bosch L., Billiau A.D., Robberecht W., and Julien J.P. Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J. Neurosci. 28 (2008) 10234-10244
8. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
9. Hall E.D., Oostveen J.A., and Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23 (1998) 249-256
10. Hensley K., Floyd R.A., Gordon B., Mou S., Pye Q.N., Stewart C., West M., and Williamson K. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82 (2002) 365-374
11. Hensley K., Fedynyshyn J., Ferrell S., Floyd R.A., Gordon B., Grammas P., Hamdheydari L., Mhatre M., Mou S., Pye Q.N., Stewart C., West M., West S., and Williamson K.S. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis. 14 (2003) 74-80
12. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., and Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191 (2005) 331-336
13. Kiaei M., Kipiani K., Petri S., Choi D.K., Chen J., Calingasan N.Y., and Beal M.F. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 93 (2005) 403-411
14. Kiaei M., Petri S., Kipiani K., Gardian G., Choi D.K., Chen J., Calingasan N.Y., Schafer P., Muller G.W., Stewart C., Hensley K., and Beal M.F. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 26 (2006) 2467-2473
15. Moreau C., Devos D., Brunaud-Danel V., Defebvre L., Perez T., Destee A., Tonnel A.B., Lassalle P., and Just N. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?. Neurology 65 (2005) 1958-1960
16. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177 (1993) 1675-1680
17. Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., and Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 10 (2007) 615-622
18. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
19. Weydt P., and Moller T. The role of microglial cells in amyotrophic lateral sclerosis. Phys. Med. Rehabil. Clin. N. Am. 16 (2005) 1081-1090 xi
20. Wilms H., Sievers J., Dengler R., Bufler J., Deuschl G., and Lucius R. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J. Neuroimmunol. 144 (2003) 139-142
21. Wu D.C., Re D.B., Nagai M., Ischiropoulos H., and Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 12132-12137